Endogenous Opioid Activity and Affective State in Insulin Resistant Women

NCT ID: NCT02069379

Last Updated: 2018-11-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2017-09-30

Brief Summary

Insulin resistance, a primary component of the metabolic syndrome, is an escalating phenomenon in the United States, and confers an increased risk of depression and mood disorder, particularly in women. The relationship between metabolic and mood disorders may be mediated by endogenous opioid activity in limbic brain regions. We propose to examine affective state and μ- opioid system function in insulin resistant women, and change in response to insulin sensitizing treatment, through the following specific aims and hypotheses:

Establish relationship between insulin resistance, affective state, and μ-opioid receptor function.

1. Insulin resistant women will have greater μ-opioid receptor availability at baseline, and a larger response to stress challenge than non-insulin resistant women

2. Insulin resistant women will have greater negative affective state at baseline, and a greater emotional response to stress challenge than non-insulin resistant women.

3. Mediational analyses will reveal that the relationship between insulin resistance and negative affect is mediated by μ-opioid receptor function and neural activation in the amygdala and nucleus accumbens affect-regulating regions.

Examine effects of insulin regulation on μ-opioid receptor function and affective state.

1. Improved insulin sensitivity will be accompanied by decreased μ-opioid receptor availability at baseline and a reduced response to stress challenge. Degree of change in baseline receptor availability and response to stress challenge after treatment will correlate with degree of insulin regulation.

2. Improved insulin sensitivity will be associated with improved affective state at baseline, and with a reduced emotional response to stress challenge. Degree of change in affective state and emotional response to stress challenge after treatment will correlate with degree of insulin regulation.

3. Mediational analyses will reveal that the change in affective state after insulin regulation is mediated by change in μ-opioid receptor function and neural activation in the amygdala and nucleus accumbens.

The expected results would suggest a role for the endogenous μ-opioid system in mediating the relationship between metabolic function and emotional processes.

Detailed Description

The objective of this study is to examine the role of the endogenous mu-opioid system in mediating the relationship between metabolic dysfunction and depressive symptoms in reproductive aged women.

PET image data was unable to be analyzed due to PET equipment replacement midway through study, leaving PET images collected at beginning of study incompatible with PET images collected later in study.

Due to insufficient enrollment in treatment arms, the 20 or 40 week data was unusable for analytic goals, so the study was re-framed for what could usefully be learned about baseline characteristics among the study populations and the originally planned outcome measures were amended to only to those that related to understanding the baseline population.

Conditions

Depression; Insulin Resistance; Metabolic Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Controls

metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Metformin

16 weeks treatment with metformin (insulin sensitizing treatment)

Group Type: EXPERIMENTAL

Metformin

Intervention Type: DRUG

Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.

Placebo

Placebo comparator to metformin treatment

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo capsules prepared identically to Metformin capsules

Interventions

Metformin

Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.

Intervention Type: DRUG

Placebo

Placebo capsules prepared identically to Metformin capsules

Intervention Type: DRUG

Other Intervention Names

Glucophage; Glumetza; Fortamet; Riomet; Sugar pills

Eligibility Criteria

Inclusion Criteria

• Women
• 18-40 years old
• metabolically healthy or insulin resistant (insulin sensitivity > 1.89x10-4 (min-1 x µU-1 x mL-1; calculated by minimal model assessment of glucose tolerance test)
• body mass index (BMI = weight (kg) / height2 (m2)) between 18 kg/m2 and 35 kg/m2.
• Women with mild or moderate depressive symptoms not meeting the criteria for Major Depressive Disorder will be included.

Exclusion Criteria

• men
• left handed
• acute medical illness
• uncorrected thyroid disease
• diabetes (fasting glucose ≥126 mg/dL)\
• neurological disease
• major depression
• substance abuse
• MRI contraindications (claustrophobia, pacemakers, pumps, metallic agents or devices)
• severe calorie restriction
• intense physical exercise ≥1 hour/day
• smoking within 6 months
• hormonal, insulin sensitizing, or centrally acting medications within 2 months
• pregnancy within 6 months
• lactation
• cardiac or pulmonary insufficiency
• liver or renal insufficiency (>2.5 x normal transaminases levels, plasma creatinine ≥1.4 mg/dL)
• history of lactic acidosis
• BMI ≥35 kg/m2
• opioid allergy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Mental Health (NIMH)

NIH

Sponsor Role: collaborator

University of Michigan

OTHER

Sponsor Role: lead

Responsible Party

Alison Berent-Spillson

Research Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Alison Berent-Spillson, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Michigan

Locations

University of Michigan Medical School

Ann Arbor, Michigan, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

K01MH095920

Identifier Type: NIH

Identifier Source: secondary_id

View Link

HUM00066696

Identifier Type: -

Identifier Source: org_study_id